SCHEMBL1719804

SCHEMBL1719804

O=c1[nH]cc(C2CCNCC2)c2ccccc12

nearest known ligand 0.66

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 9/20 0.66
ADRB2 P07550 1/20 0.66
HTR6 P50406 2/20 0.48
IKBKB O14920 1/20 0.46
CHUK O15111 1/20 0.46
GABRA1 P14867 1/20 0.43
GABRG2 P18507 1/20 0.43
GABRB3 P28472 1/20 0.43
PARP1 P09874 1/20 0.43
SLC18A3 Q16572 1/20 0.43
SIGMAR1 Q99720 1/20 0.43
APP P05067 1/20 0.43
KDM4E B2RXH2 1/20 0.42
HTR2A P28223 1/20 0.42
KCNH2 Q12809 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1719768 0.98 HTR2C (0.67) HTR2CADRB2HTR6IKBKBCHUK
SCHEMBL4077866 0.90 HTR2C (0.54) HTR2CADRB2HTR6IKBKBCHUK
Hydrochloric Acid SCHEMBL1719553 0.89 HTR2C (0.55) HTR2CADRB2HTR6IKBKBCHUK
SCHEMBL11817106 0.85 HTR2C (0.46) HTR2CADRB2PARP1KDM4E
SCHEMBL1720032 0.80 HTR2C (0.47) HTR2CADRB2HTR6IKBKBCHUK
SCHEMBL1720620 0.80 APP (0.47) HTR2CADRB2HTR6PARP1APP
SCHEMBL1720025 0.80 KDM4E (0.57) HTR6APPKDM4EHTR2A
SCHEMBL29502102 0.79 HTR2C (1.00) HTR2CADRB2APPKDM4EHTR2A
SCHEMBL373923 0.79 HTR2C (1.00) HTR2CADRB2APPKDM4EHTR2A
Hydrochloric Acid SCHEMBL1720415 0.79 HTR2C (0.48) HTR2CADRB2HTR6IKBKBCHUK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1566380-B1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2012-01-11 EP claimed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US claimed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US claimed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP claimed
EP-1566380-B1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2012-01-11 EP disclosed
EP-1566380-B1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2012-01-11 EP disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US disclosed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof PARP1, NQO1, PARP3 HTR2C 2811/4885ADRB2 3775/4885HTR6 3033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.